Novo Nordisk

Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases. The Biopharm segment focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1925 is headquartered in Bagsværd, Denmark.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk reported forecast-beating quarterly sales of its popular Wegovy weight-loss drug on Wednesday, sending its shares up nearly 9%.

Novo Nordisk CEO on Wegovy prices, supplies and compounding

Novo Nordisk on Wednesday nudged higher its outlook for the year as the drugmaker registered another quarter of strong sales of its weight-loss drugs.

Ozempic maker Novo Nordisk nudges higher profit forecast

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 drugs already on the market, and reiterated its expectation the new injection will deliver 25% weight loss.

Novo Nordisk says its experimental drug CagriSema has similar side effects to Wegovy

Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Novo Nordisk lifts curbs on Wegovy prescriptions in the U.S., says CEO

Novo Nordisk is aware of 100 hospitalizations and 10 deaths resulting from people taking compounded copies of its popular weight-loss and diabetes drugs, the drugmaker's finance chief said on Wednesday.

Novo Nordisk says it is aware of 10 deaths from compounded weight-loss drug copies

Novo Nordisk (NYSE:NVO) reported better-than-expected third-quarter sales of its weight-loss drug Wegovy, reaching $2.49 billion, exceeding analyst expectations of $2.29 billion and increasing 48% from the previous quarter. The strong performance is seen as a positive sign amid competition from Eli Lilly's obesity drug, Zepbound.

Novo Nordisk Q3 numbers boosted by Wegovy beat

The pharmaceutical giant narrowed its full-year guidance after its blockbuster Wegovy weight-loss drug beat sales expectations in the third quarter.

Novo Nordisk's Wegovy Sales Beat Expectations

Novo Nordisk quarterly profit meets expectations as Wegovy maker narrows full-year guidance

Bagsværd, 6 November 2024  - Financial report for the period 1 January 2024 to 30 September 2024

Novo Nordisk's sales increased by 23% in Danish kroner and by 24% at constant exchange rates to DKK 204.7 billion in the first nine months of 2024

Weight-loss and diabetes drugmaker Novo Nordisk on Wednesday posted third-quarter operating profit in line with expectations and narrowed its full-year sales and profit guidance range.

Novo Nordisk Q3 in line with expectations, narrows FY guidance range

Investors want assurance the new GLP-1 weight-loss medicines can live up to their blockbuster expectations.

Novo Nordisk Earnings Are Soon. It's All About Weight-Loss Drug Sales.

Gilead Sciences

Moderna

Teva Pharmaceutical

Viatris

Let us look at five large biotech and generic drug companies, NVO, GILD, MRNA, VTRS and TEVA, which are gearing up for their earnings releases this week.

What's in Store for These 5 Drug & Biotech Stocks in Q3 Earnings?

Novo Nordisk AS NVO will report third-quarter earnings on Wednesday. Wall Street expects 88 cents in EPS and $10.49 billion in revenues when the company reports after market hours.

Novo Nordisk Q3 Preview: Will $285 Million Weight Loss Bet Offset Bearish Charts?

Hims & Hers Health

The telehealth company will launch a generic version of Novo's type 2 diabetes drug liraglutide in 2025.

Hims & Hers Stock Jumps. A Generic Version of Novo Nordisk Diabetes Drug Is Close.

Catalent

Contract drug manufacturer Catalent , which is in the process of being acquired by Novo Holdings, posted a surprise first-quarter loss and revenue below Wall Street estimates on Tuesday.

Catalent misses Q1 revenue estimates ahead of $16.5 bln deal close with Novo Holdings

Eli Lilly

Americans are still eagerly seeking prescriptions for Eli Lilly and Novo Nordisk's weight-loss and diabetes drugs but cannot always fill them because of supply issues and insurance hurdles, according to their doctors.

Americans seeking Eli Lilly and Novo Nordisk's weight-loss drugs turn to compounded market

Ambev

Automatic Data Processing

ASML Hld

ConocoPhillips

Cintas Corp

Dick's Sporting Goods

Devon Energy

EOG Resources

Diamondback Energy

Hershey

Infosys

Lam Research

Monolithic Power Systems

MSCI

Old Dominion Freight Line

Paychex

Rollins

Schwab US Dividend Equity ETF

Visa

Watsco

The 4-factor dividend growth portfolio is a strategy that leverages the stock selection process of Schwab U.S. Dividend Equity ETF with a few minor twists. The portfolio finished FY2 on October 31, 2024, with a total return of 33.27%. Since its inception, the portfolio has generated a CAGR of 21.57%, and is outperforming SCHD by 10.30%.

4-Factor Dividend Growth Portfolio: FY3 Rebalance And 21.57% Long-Term CAGR

Telehealth firm Hims & Hers Health said on Monday it plans to bring a generic version of Novo Nordisk's diabetes drug, liraglutide, to its platform in 2025.

Hims & Hers Health plans to offer generic version of Novo Nordisk's diabetes drug in 2025

Novo Nordisk (NVO), maker of popular weight-loss drugs Ozempic and Wegovy, is set to report third-quarter earnings Wednesday morning, with Wall Street analysts generally bullish on the Danish drugmaker's stock.

What Wall Street Analysts Think of Novo Nordisk's Stock Ahead of Earnings

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?

NVO's third-quarter revenues are expected to have been driven by its diabetes and obesity care product sales, especially Wegovy, Ozempic and Rybelsus.

Novo Nordisk Before Q3 Earnings: How Should Investors Play the Stock?

Airbnb

Marriott

Ferrari

Super Micro Computer

U.S. Election Day, a Federal Reserve meeting, and earnings reports from around 100 S&P 500 companies.

Super Micro, Ferrari, Marriott, Airbnb, Novo Nordisk, and More Stocks to Watch This Week

Novo Nordisk (NYSE:NVO) has reported another successful trial for its Wegovy or  Semaglutide drug, this time in the treatment of fibrosis caused by the fatty liver condition known as MASH. Headline results from part 1 of the ongoing ESSENCE trial, a phase three, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis, showed it met its primary endpoint, Compared to placebo there was a statistically significant and superior improvement in liver fibrosis with no worsening of steatohepatitis, said the Danish group which is Europe's largest company.

Wegovy effective in MASH fatty liver fibrosis trial says Novo

Novo Nordisk said on Friday its weight-loss drug Wegovy met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis.

Novo's Wegovy helps improve liver fibrosis in late-stage trial

Bagsværd, Denmark, 1 November 2024 – Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, double-blinded trial in 1,200 adults with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to advanced liver fibrosis (stage 2 or 3)1. Part 1 of the ESSENCE trial evaluated the effect of once-weekly semaglutide 2.4 mg on liver tissue (histology) compared to placebo on top of standard of care for the first 800 randomised people at 72 weeks.

Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial

News for Novo Nordisk Stock (NVO)